This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''3-Hydroxyphencyclidine''' (commonly known as '''3-HO-PCP''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class that produces potent, highly dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. In addition to its primary activity as a [[NMDA receptor antagonist]], it has been found to have appreciable affinity for the mu [[opioid]] receptor.
'''3-Hydroxyphencyclidine''' (commonly known as '''3-HO-PCP''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class that produces potent, highly dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. In addition to its primary activity as a [[NMDA receptor antagonist]], it has been found to have appreciable affinity for the [[μ-opioid]] [[receptor]].<ref name="3HOPCPmu">Itzhak, Y., Kalir, A., & Sarne, Y. (1981). On the opioid nature of phencyclidine and its 3-hydroxy derivative. European Journal of Pharmacology, 73(2-3), 229-233.</ref>
The compound was first synthesized in 1978 to investigate the structure-activity relationship of [[phencyclidine]] (PCP) derivatives.<ref>Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O.
The compound was first synthesized in 1978 to investigate the structure-activity relationship of [[phencyclidine]] (PCP) derivatives.<ref>Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O.
Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> It was further explored alongside [[PCP]] in the 1980s, where it was discovered to possess [[opioid]] activity in animal models.<ref>Itzhak, Y., Kalir, A., & Sarne, Y. (1981). On the opioid nature of phencyclidine and its 3-hydroxy derivative. European Journal of Pharmacology, 73(2-3), 229-233.</ref> Its potential as a [[research chemical]] for human use was not suggested until 1999 when a chemist using the pseudonym John Q. Beagle reported on its significantly increased potency relative to PCP as well as its profoundly enhanced affinity for the opiate receptor" which was estimated to give it analgesic activity 1 order of magnitude lower than [[morphine]].<ref>Beagle, J. Q. (1999). Structure Activity of PCP analogs. Retrieved from https://erowid.org/archive/rhodium/chemistry/pcp/sar.html#sarphenyl</ref><ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>
Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> It was further explored alongside [[PCP]] in the 1980s, where it was discovered to possess [[μ-opioid]] [[agonist]] activity in animal models.<ref name="3HOPCPmu" /> Its potential as a [[research chemical]] for human use was not suggested until 1999 when a chemist using the pseudonym John Q. Beagle reported on its significantly increased potency relative to PCP as well as its "profoundly enhanced affinity for the opiate receptor" which was estimated to give it analgesic activity one order of magnitude lower than [[morphine]].<ref>Beagle, J. Q. (1999). Structure Activity of PCP analogs. Retrieved from https://erowid.org/archive/rhodium/chemistry/pcp/sar.html#sarphenyl</ref><ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>
Like other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is known to primarily induce a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", albeit the extent to which this occurs has been reported to be highly dose-dependent and variable in its effects.{{citation needed}}
Like other substances of its class, particularly [[methoxetamine]] (MXE), [[phencyclidine]] (PCP), and [[3-MeO-PCE]], it is known to primarily induce a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", albeit the extent to which this occurs has been reported to be highly dose-dependent and variable in its effects.{{citation needed}} There are also reports that suggest this compound may produce more physical side effects such as muscle soreness and flu-like symptoms during or shortly after administration. This suggests it may be uniquely more dangerous or toxic than related dissociatives, particularly at higher doses.
Today, 3-HO-PCP is almost exclusively distributed as a gray area [[research chemical]] through the use of online vendors.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> Due to its potent dissociative and [[opioid]] effects, reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
Today, 3-HO-PCP is almost exclusively distributed as a gray area [[research chemical]] by online vendors.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> Due to its potent dissociative and [[opioid]] effects, reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
The compound was first synthesized in 1978 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives.[2] It was further explored alongside PCP in the 1980s, where it was discovered to possess μ-opioidagonist activity in animal models.[1] Its potential as a research chemical for human use was not suggested until 1999 when a chemist using the pseudonym John Q. Beagle reported on its significantly increased potency relative to PCP as well as its "profoundly enhanced affinity for the opiate receptor" which was estimated to give it analgesic activity one order of magnitude lower than morphine.[3][4]
Like other substances of its class, particularly methoxetamine (MXE), phencyclidine (PCP), and 3-MeO-PCE, it is known to primarily induce a state referred to as "dissociative anesthesia", albeit the extent to which this occurs has been reported to be highly dose-dependent and variable in its effects.[citation needed] There are also reports that suggest this compound may produce more physical side effects such as muscle soreness and flu-like symptoms during or shortly after administration. This suggests it may be uniquely more dangerous or toxic than related dissociatives, particularly at higher doses.
Today, 3-HO-PCP is almost exclusively distributed as a gray area research chemical by online vendors.[5] Due to its potent dissociative and opioid effects, reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if choosing to use this substance.
As a result, it may contain incomplete or wrong information. You can help by expanding it.
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.[6]
Chemistry
3-HO-PCP, or 3-hydroxyphencyclidine, is a synthetic dissociative of the arylcyclohexylamine class. 3-HO-PCP contains cyclohexane, a six-member saturated ring, bonded to two additional rings at R1. One of these rings is a piperidine ring, a nitrogenous six member ring, bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R3 with a hydroxy group.
3-HO-PCP is a PCP analog and structurally homologous to 3-MeO-PCP.
3-HO-PCP acts as an NMDA receptor antagonist. A specific subtype of glutamate receptor, NMDA (N-Methyl-D-Aspartate), modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open. Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia.[citation needed]
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Spontaneous physical sensations - The body high of this compound can be described in terms of its style variations as a motionless, constant, sharp, all-encompassing, and euphoric activation of nerve endings across the body.
Physical euphoria - 3-HO-PCP has been reported to more readily induce euphoria than most other dissociatives, such as ketamine or diphenidine, especially of the manic variant.
Tactile enhancement and Tactile suppression - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and anesthesia.
Pain relief - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
Bodily control enhancement and Motor control loss - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control
Seizure - This extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued or undernourished.
Compulsive redosing - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
Mania - This effect is reportedly more common on 3-HO-PCP than most other dissociatives. It typically occurs during the offset of the trip, but can also occur during the onset and come up as well.
Psychosis - This effect has been reported to be more common on 3-HO-PCP than most other dissociatives, such as MXE or Ketamine. It typically occurs during the offset of the trip, but can also occur during the onset and come up as well.
Delusions - Like psychosis, this effect is reportedly more common on 3-HO-PCP than most other dissociatives.
Visual acuity enhancement - This effect has been reported as being especially present at low dosages.
Visual acuity suppression - While lower doses of this compound tend to produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
The toxicity and long-term health effects of recreational 3-HO-PCP use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-HO-PCP has a very short history of human usage.
Tolerance and addiction potential
The chronic use of 3-HO-PCP can be considered highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, 3-HO-PCP has been reported to be more addictive than MXE, diphenidine, ephenidine, DCK, and ketamine. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.
Tolerance to many of the effects of 3-HO-PCP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 4 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-HO-PCP presents cross-tolerance with [[Cross-tolerance::all dissociatives]], meaning that after the consumption of 3-HO-PCP, all dissociatives will have a reduced effect.
It is strongly recommended that one exercise extreme caution and harm reduction practices when using this substance.
Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.
The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.[7]
Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the administration of the intended dose.
Urinary tract effects
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-HO-PCP is likely to exhibit similar bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is possibly because 3-HO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
Urinary urgency - This can be described as a sudden, compelling need to urinate.
Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
Hematuria - Hematuria is visible blood in the urine.
Incontinence - This is the leakage of urine.
All of these, however, can be avoided by refraining from using 3-HO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.
As such, it may contain incomplete or wrong information. You can help by expanding it.
United Kingdom - 3-HO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with a hydroxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.[8]
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs.Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
References
↑ 1.01.1Itzhak, Y., Kalir, A., & Sarne, Y. (1981). On the opioid nature of phencyclidine and its 3-hydroxy derivative. European Journal of Pharmacology, 73(2-3), 229-233.
↑Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O.
Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.
↑Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
↑Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
↑ "(ACMD) Methoxetamine Report (2012)" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.
